Stockscreener 앱 받기
3.98
0.75%
-0.03
시간 외 거래:
4.08
0.10
+2.51%
Arbutus Biopharma Corp 주식(ABUS)의 최신 뉴스
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Aug Drivers: Can Arbutus Biopharma Corporation ride the EV waveQuarterly Investment Review & Consistent Return Strategy Ideas - baoquankhu1.vn
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus (ABUS) upgraded to buy: Here's what you should know - MSN
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Arbutus Biopharma Shares Fall 19% On European Patent Revocation - Nasdaq
Arbutus Biopharma (ABUS) Patent Revocation Leads to 14% Pre-Market Drop - Intellectia AI
European Patent Office revokes Arbutus Biopharma patent following appeal - Investing.com
Arbutus Biopharma CorpEPO revokes Arbutus Biopharma's European patent EP 2279254SEC filing - marketscreener.com
Weekly Trades: Will Arbutus Biopharma Corporation stock gain from lower inflationTrade Signal Summary & Stock Market Timing Techniques - Bộ Nội Vụ
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus (ABUS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How sustainable is Arbutus Biopharma Corporation stock dividend payoutBear Alert & Safe Entry Momentum Stock Tips - Улправда
Why Arbutus Biopharma Corporation stock is popular among millennialsQuarterly Portfolio Summary & Long-Term Growth Plans - Улправда
New Highs: Why Arbutus Biopharma Corporation stock is popular among millennialsEarnings Miss & Growth-Oriented Investment Plans - Улправда
What is the fair value of Arbutus Biopharma Corporation stock nowWeekly Trading Summary & Weekly Momentum Picks - Улправда
Will Arbutus Biopharma Corporation stock deliver shareholder valueWeekly Market Report & Fast Entry Momentum Alerts - Улправда
How Arbutus Biopharma Corporation stock reacts to Fed rate cutsQuarterly Portfolio Summary & Weekly High Momentum Picks - Улправда
Is Arbutus Biopharma Corporation stock supported by strong fundamentals2025 Pullback Review & Consistent Income Trade Recommendations - Улправда
Why Arbutus Biopharma Corporation stock is seen as undervaluedProduct Launch & Low Drawdown Trading Strategies - Улправда
Hepatitis B Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Arbutus Biopharma, GSK/Ionis Pharma, Vir Biotech, Dong-A ST Co., Ltd., Barinthus Biotherapeutics, GC Biopharma Corp - The Globe and Mail
Hepatitis B Market to Witness Promising Upswing by 2034, - openPR.com
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6%Still a Buy? - MarketBeat
Pharma Patent Trials Loom in 2026 for Wegovy, Covid-Vaccine Tech - Mintz
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Why Arbutus Biopharma Corporation stock is rated strong buyEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
ABUS (Arbutus Biopharma) OCF Margin % : -1,099.62% (As of Sep. 2025) - GuruFocus
Is Arbutus Biopharma Corporation stock ready for breakoutCEO Change & Reliable Entry Point Alerts - ulpravda.ru
Does Arbutus Biopharma Corporation stock trade at a discount to peersPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4%What's Next? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.6%Should You Buy? - MarketBeat
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
[8-K] Arbutus Biopharma Corp Reports Material Event | ABUS SEC FilingForm 8-K - Stock Titan
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
New Haven biotech names new CFO - Hartford Business Journal
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
1.12%
0.87%
자본화:
|
볼륨(24시간):